This IASLC meeting is designed to provide information about ongoing clinical trials of the newest therapies for Mesothelioma. The meeting presenters will summarize data on relevant targets for new therapies. Data on preclinical and early clinical data will be presented for each of the drugs directed against these targets. The meeting will also present data on early predictive biomarkers. Additionally, there will be presentations from fellows and young investigators in training and debates about controversial topics. The meeting is a unique resource for clinical investigators, including those in academia, clinical practice and industry.

Live Activity Date: July 10 - 12, 2019

Healthcare professionals who diagnose and treat patients with mesothelioma, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants. 

Upon completion of this activity, the participants should be able to: 

• For clinical mesothelioma investigators to understand the science behind emerging therapies.
• Recognize and plan teh most novel and relevant scientific trials of new therapies.

Program Co-Chairs: 

• Michele Carbone, MD, University of Hawaii Cancer Center, Honolulu, HI, USA
• Rafael Bueno, MD, Chief Division of Thoracic Surgery, Frederic G. Levin Distinguished Chair of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
• Harvey Pass, MD, NYU Langone Health, New York, NY, USA
• Anne Tsao, MD, Professor, MD Anderson Cancer Center, Houston, TX, USA

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need assistance with this activity, please email: education@iaslc.org.